INBX Stock Jumps As Ozekibart Data Draws $150 Target

Inhibrx Biosciences Inc. stocks have been trading up by 36.88 percent amid heightened investor optimism from recent positive developments

Live Update At 16:01:57 EDT: On Wednesday, April 22, 2026 Inhibrx Biosciences Inc. stock [NASDAQ: INBX] is trending up by 36.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INBX has traded like a biotech rocket lately. From 2026/03/30 to 2026/04/21, Inhibrx Biosciences Inc. climbed from a close near $59.88 to $84.08. Then, on 2026/04/22, the stock exploded intraday to a $155.29 high before closing at $115.61. That’s huge volatility, the kind momentum traders hunt.

The 5‑minute chart shows a classic spike‑and‑fade. INBX opened at $147.50, ripped to the mid‑$150s, then sold off hard toward $100 before grinding back into the mid‑$110s by the close. Liquidity was there, but so was serious range risk.

Fundamentally, INBX is still a classic clinical‑stage biotech story. Revenue is tiny at about $1.3M, while the latest quarterly net loss is around $32.8M. The company burned roughly $30.1M in free cash flow for the quarter, yet held $124.2M in cash at 2025/12/31. That gives Inhibrx Biosciences Inc. some runway but not endless time.

More Breaking News

• QXO Stock Grinds Higher As Traders Focus On Turnaround Setup
• Alaska Air Group ALK Jumps After AI Maintenance Deal And Analyst Support
• ROAD Stock Jumps As Construction Partners Wins Upgrade And Expands In Nashville
• RPAY Jumps As Forager Launches $4.80 Cash Takeover Bid

Valuation is rich on paper. With a price‑to‑sales ratio near 925.7 and price‑to‑book over 150, traders are clearly paying for pipeline potential, not current earnings. Loss margins are massive, and returns on equity and assets are sharply negative. For active traders, that combo — cash runway plus high expectations — means INBX will trade off news flow and sentiment, not traditional value metrics.

Why Traders Are Watching INBX Momentum

INBX is front and center right now because the science narrative just lined up with the chart. Inhibrx Biosciences Inc. reported updated interim Phase 1/2 data for ozekibart (INBRX‑109) plus FOLFIRI in heavily pretreated metastatic colorectal cancer, and the numbers turned heads. A 20% objective response rate with 87% disease control in a beaten‑up population matters. Add a 5.5‑month median progression‑free survival and a manageable safety profile, and traders see real drug potential, not just hype.

For a small clinical‑stage name like INBX, that kind of signal is the fuel behind those wild intraday swings. The stock’s parabolic move on 2026/04/22 lines up neatly with a market that suddenly believes ozekibart has multiple “shots on goal.” Inhibrx Biosciences Inc. is not just talking about one niche; it’s mapping a full regulatory campaign.

The company plans an FDA meeting in the second half of 2026 to kick off a first‑line registrational colorectal cancer trial. At the same time, INBX is exploring accelerated pathways in fourth‑line colorectal cancer and refractory Ewing sarcoma. On top of that, Inhibrx Biosciences Inc. has already submitted a BLA for ozekibart in conventional chondrosarcoma after a positive registrational trial.

Those are real catalyst dates and decision points that traders can circle on a calendar. Street validation adds more fuel. Stifel has initiated coverage of INBX with a Buy rating and a $150 price target, calling out both ozekibart and INBRX‑106 plus the proof‑of‑concept in chondrosarcoma. Another Stifel note echoed the same $150 target, signaling growing confidence that Inhibrx Biosciences Inc. has meaningful upside from its oncology pipeline. When clinical data, a clear FDA roadmap, and a fresh high price target all hit together, momentum traders pay attention.

Conclusion

For active traders, INBX now sits in that sweet spot where story and price action collide. Inhibrx Biosciences Inc. is still burning cash, still reporting steep losses, and still trading at eye‑watering valuation multiples. But the market isn’t paying Inhibrx Biosciences Inc. for current profits. It’s paying for the chance that ozekibart and the broader INBX pipeline become real revenue machines down the road.

The updated ozekibart plus FOLFIRI data in metastatic colorectal cancer gives that story teeth. The BLA in conventional chondrosarcoma provides a nearer‑term regulatory swing. The planned FDA meeting in 2H26 and exploration of accelerated pathways in tougher colorectal and Ewing sarcoma settings add more potential catalysts that can reprice INBX quickly, in both directions.

Stifel’s Buy rating and $150 target underscore how aggressively some on the Street are willing to underwrite that risk‑reward profile. For day traders and swing traders, INBX is now a textbook catalyst play — big range, heavy news, and a clear narrative to track. As Tim Sykes likes to say, “Volatility is your best friend if you respect it and cut losses quickly.” That dovetails with another staple of disciplined trading psychology: as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” With INBX, that mindset is essential. This is a news‑driven biotech, not a sleepy blue chip, and every headline tied to ozekibart or INBRX‑106 can shift the game fast.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.